UNI-EN 23:Judgement in litigation relating to alleged infringement of the patent relating to montelukast in Slovenia
Firma: KRKA, TOVARNA ZDRAVIL D.D.Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 23 | / | 2012 | | ||||||
| Date of issue: | 2012-07-13 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| Judgement in litigation relating to alleged infringement of the patent relating to montelukast in Slovenia | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Krka, d. d., Novo mesto (hereinafter as “Krka") announces to the interested public that Krka received the judgement of the High Court in Ljubljana which refused the appeal filed by company Merck Frosst Canada Limited, Purdy's Wharf Tower One, 1959 Upper Water Street, Halifax, Nova Scotia, Canada (hereinafter as “MSD") and confirmed the decision of the District Court in Ljubljana dated 15 March 2010 which refused the motion filed by MSD against Krka and Salus, Ljubljana, d. d. for alleged infringement of its patent relating to the active ingredient montelukast. The plaintiff claimed that the court bans manufacturing, offering for sale, marketing, and importing of the product Monkasta or any other product containing active pharmaceutical ingredient montelukast to defendants in Slovenia and claimed the damages for the patent infringement. The decision of the District Court in Ljubljana is final. Plaintiff has the option to file the revision against that decision to the Supreme Court. Krka published the information relating to montelukast dispute in Slovenia on 23 March 2010, 23 April 2009, 5 December 2008, 13 March 2008 and 14 June 2007. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2012-07-13 | Jože Colarič | President of the Management Board | |||
Cena akcji Krka
Cena akcji Krka w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Krka aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Krka.
